Daiichi discontinues anorexia program

Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) said it discontinued development of SUN11031, a human ghrelin that was in Phase III testing in Japan to treat anorexia nervosa. The pharma said that th...